|
Index | - | P/E | - | EPS (ttm) | -1.97 | Insider Own | 17.20% | Shs Outstand | 5.24M | Perf Week | -9.03% |
Market Cap | 94.99M | Forward P/E | - | EPS next Y | - | Insider Trans | -3.81% | Shs Float | 3.49M | Perf Month | -17.08% |
Income | -9.30M | PEG | - | EPS next Q | - | Inst Own | 6.50% | Short Float | 13.22% | Perf Quarter | 58.66% |
Sales | - | P/S | - | EPS this Y | -130.90% | Inst Trans | 81.94% | Short Ratio | 0.26 | Perf Half Y | -63.30% |
Book/sh | 0.91 | P/B | 4.43 | EPS next Y | - | ROA | -76.60% | Target Price | - | Perf Year | -60.95% |
Cash/sh | 0.02 | P/C | 189.97 | EPS next 5Y | - | ROE | -156.80% | 52W Range | 1.90 - 11.50 | Perf YTD | 47.62% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -64.96% | Beta | -0.84 |
Dividend % | - | Quick Ratio | 0.10 | Sales past 5Y | - | Gross Margin | - | 52W Low | 112.11% | ATR | 0.72 |
Employees | 2 | Current Ratio | 0.10 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 43.65 | Volatility | 13.27% 15.47% |
Optionable | Yes | Debt/Eq | 0.55 | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.42 | Prev Close | 3.94 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 1.77M | Price | 4.03 |
Recom | - | SMA20 | -21.77% | SMA50 | 1.71% | SMA200 | -48.19% | Volume | 750,403 | Change | 2.28% |
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite